A manufacturer for advanced medicines

For Oxford BioMedica (LSE:OXB), Demand for the manufacture of cell and gene therapies is what drives the FTSE 250 company. Oxford BioMedica is a contract development and Manufacturing organisation, or CDMO, specialising in the complex production of viral vectors and other components used in advanced cell and gene therapies. Rather than developing its own drugs, it makes these difficult-to-produce therapies for pharmaceutical and biotech clients. As cell and gene therapies advance and more reach patients, demand for specialist manufacturing capacity should grow, so the pipeline of client programmes and the company's ability to win and deliver contracts shape its prospects.

Turning profitable

The full-year 2025 results, for the year ended 31 December 2025 and reported on 26 March 2026, marked an important milestone. Total Revenue rose 33% on a constant-currency basis to £170.9m, and the company reported operating EBITDA of £8.1m, against a £15.3m loss the prior year, its first full year of operating profitability, according to its reporting. Year-end cash rose to £96.9m from £60.7m, with net cash of £55.4m. For 2026 the company guided to revenue of £220m to £240m, with around 60% already covered by contracted orders, double-digit margins expected in the second half, and a long-term EBITDA Margin target approaching 30%. These are reported figures and guidance. Reaching profitability is significant for a Business that had long invested ahead of revenue.

Scaling a specialist capability

Oxford BioMedica's Investment case rests on the growth of cell and gene therapies and the difficulty of manufacturing them, which favours specialists with proven capacity. The 33% revenue growth and move into operating profit suggest the CDMO model is gaining scale, and the high proportion of 2026 revenue already contracted provides visibility. The long-term margin target approaching 30% indicates the potential profitability of the business as it scales. The key questions are whether client demand and the broader cell and gene therapy market keep growing, and whether the company can convert its pipeline into contracts and deliver them profitably at scale. Ending the year with cash of £96.9m and net cash of £55.4m gives the financial stability a capital-intensive manufacturer needs. Guidance that around 60% of 2026 revenue is already covered by contracted orders provides unusual visibility, and the long-term EBITDA margin ambition approaching 30% points to the profitability well ahead.

Opportunities and risks

The opportunity is rising demand for the specialist manufacture of cell and gene therapies, with Oxford BioMedica newly profitable, growing revenue, and targeting attractive long-term margins as it scales. The risks include dependence on the progress of clients' therapy programmes, which can be delayed or cancelled, and the concentration risk of a CDMO reliant on a limited number of large contracts. The cell and gene therapy field is still maturing, competition in manufacturing is growing, and margins depend on capacity utilisation. Early profitability is encouraging but must be sustained, and a slowdown in the therapy market would reduce demand for manufacturing.

The bottom line

Cell and gene therapy demand shapes Oxford BioMedica because manufacturing these advanced medicines for others is its entire business. The year to December 2025 delivered 33% revenue growth and a first full year of operating profitability, with 2026 guidance for further growth and a high proportion of revenue already contracted. For readers, the questions are whether the cell and gene therapy market keeps expanding, whether the company can win and deliver contracts profitably at scale, and whether it hits its long-term margin ambition. Reaching profitability is a real turning point, but sustaining growth and utilisation in a maturing, competitive field is the key test for shareholders over time.